<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004935</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 22/99</org_study_id>
    <secondary_id>SWS-SAKK-22/99</secondary_id>
    <secondary_id>EU-99028</secondary_id>
    <nct_id>NCT00004935</nct_id>
  </id_info>
  <brief_title>Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2</brief_title>
  <official_title>Randomized Phase III Trial of Herceptin® Followed by Chemotherapy Plus Herceptin® Versus the Combination of Herceptin® and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: To compare efficacy, toxicity and quality of life of the sequential administration
      of Her alone followed, at PD, by the combination with Chemotherapy (Arm A) vs. the upfront
      combination of Her and Chemotherapy (Arm B) in patients with advanced/metastatic breast
      cancer.

      PURPOSE: Trial SAKK 22/99 addresses clinically relevant and currently unresolved questions
      regarding the optimal use of Herceptin in the treatment of patients with advanced/metastatic
      breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 30, 1999</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">November 6, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression on combined HerChemo (TTPHerChemo)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first progression</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of serum HER2/neu ECD levels on clinical outcome</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate of estrogen receptor status</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of immunoprofiles of erbB-1, erbB-2, erbB-3 and erbB-4 with clinical outcome</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Herceptin™ (Her)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herceptin™+Chemo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin™ (Her)</intervention_name>
    <description>Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy</description>
    <arm_group_label>Herceptin™ (Her)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin™ (Her) + chemo</intervention_name>
    <description>Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy</description>
    <arm_group_label>Herceptin™+Chemo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed HER2-overexpressing metastatic breast carcinoma

          -  Clinically or radiologically measurable or evaluable disease

               -  Bidimensionally or unidimensionally measurable lesions

          -  No ascitic, pleural, or pericardial effusions, osteoblastic bone metastases, or
             carcinomatous lymphangitis of the lung as only indicator lesion

          -  No known clinical brain or meningeal involvement

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 70

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  ECOG 0-1 OR

          -  SAKK 0-1

        Life expectancy:

          -  At least 12 weeks

        Hematopoietic:

          -  Hemoglobin at least 10 g/dL

          -  Platelet count at least 100,000/mm^3

          -  Absolute neutrophil count at least 2,000/mm^3

        Hepatic:

          -  Bilirubin normal

          -  SGOT and/or SGPT no greater than 2 times upper limit of normal (ULN) (3 times ULN if
             proven liver metastases) OR

          -  No SGOT and/or SGPT greater than 1.5 times ULN if alkaline phosphatase greater than
             2.5 times ULN

        Renal:

          -  Creatinine no greater than 1.25 times ULN

        Cardiovascular:

          -  LVEF normal

          -  No history of atrial ventricular arrhythmia, congestive heart failure, or angina
             pectoris, even if medically controlled

          -  No history of second or third-degree heart blocks

          -  No uncontrolled hypertension

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No pre-existing motor or sensory neuropathy grade 2 or greater

          -  No psychiatric disorder that would preclude informed consent

          -  No other prior malignancy except curatively treated nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  No definite contraindications for use of corticosteroids

          -  No other concurrent serious illness or medical condition

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Prior adjuvant or neoadjuvant chemotherapy allowed

          -  No more than 2 prior chemotherapy regimens for metastatic disease

          -  No prior cumulative dose of doxorubicin greater than 240 mg/m^2

          -  No prior cumulative dose of epirubicin greater than 360 mg/m^2

          -  No prior taxanes

        Endocrine therapy:

          -  Prior hormonal therapy as adjuvant treatment or for metastatic disease allowed

          -  No concurrent corticosteroids unless started more than 6 months prior to study and at
             low doses (i.e., no greater than 20 mg methylprednisolone or equivalent)

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  No other concurrent anticancer drugs

          -  No other concurrent experimental drugs

          -  No concurrent bisphosphonates unless initiated more than 3 months prior to study

               -  Chronic use allowed provided bone metastases are not sole indicator lesions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pagani Olivia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Oncologico della Svizzera Italiana IOSI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Beata Vergine</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH-6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Beretta</name>
      <address>
        <city>Rheinfelden</city>
        <zip>CH-4310</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum</name>
      <address>
        <city>Zurich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

